After coronary thrombolysis and reperfusion, What next?

Journal of the American College of Cardiology

Volumn 14, Issue 4, 1989, Pages 837-849

  Bang, Nils U ^a   Wilhelm, Olaf G ^a   Clayman, Michael D ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXYLIC ACID 2 HYDROXY 1 METHYLPROPYL ESTER; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ALTEPLASE; ANISTREPLASE; ANTICOAGULANT AGENT; HEPARIN; PEPTIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; STREPTOKINASE;

ADULT; AGED; BLEEDING; BLOOD CLOT LYSIS; FEMALE; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTICOAGULANTS; ASPIRIN; FIBRINOLYTIC AGENTS; HEPARIN; HUMAN; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; THROMBOLYTIC THERAPY;

EID: 0024419851     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(89)90454-3     Document Type: Conference Paper

References (107)

1. The maintenance of a sustained thrombolytic state in man. 11. Clinical observation on patients with myocardial infarction and other thromboembolic disorders
2. Thrombolytic therapy in myocardial infarction
3. Thombolytic therapy in myocardial infarction
4. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology
5. Thrombolysis in Myocardial Infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator
6. Announcement of protocol change in Thrombolysis in Myocardial Infarction Trial (letter)
7. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase 1: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase
8. Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction
9. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
10. Acute coronary artery obstruction in myocardial infarction: overview of thrombolytic therapy
11. Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: preduction of clinical outcome
12. 2 and serotonin after thrombolysis with tissue-type plasminogen activator in canine preparation of coronary thrombosis
13. Prediction of infarct coronary recanalization after intravenous thrombolytic therapy
14. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis
15. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction
16. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty
17. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction
18. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction
19. Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I Trial
20. Comparison of left ventricular function and contractile reserve after successful recanalization by thrombolysis versus rescue percutaneous transluminal coronary angioplasty for acute myocardial infarction
21. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction
22. Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction
23. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction
24. Comparative randomized study of the effectiveness of intravenous tissue-type plasminogen activator and intravenous streptokinase in patients with actue myocardial infarction
25. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate
26. Intracoronary thrombolysis in evolving myocardial infarction
27. Myocardial salvage after intracoronary thrombolysis with streptokinase in myocardial infarction
28. Tissue plasminogen activator (t-PA) resistant platelet rich white thrombus (WT) and combination treatment of t-PA and anti-platelet antibody to GPIIb/IIIa receptor (7E3)
29. Intravenous tissue plasminogen activator and size of infarct, left ventricular function. and survival in acute myocardial infarction
30. The Thrombolysis in Myocardial Infarction (TIMI) Trial
31. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET)
32. Limitations of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator
33. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction
34. Randomized trial of intravenous streptokinase oral aspirin both or neither among 17187 cases of suspected acute myocardial infarction ISIS 2
35. The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomized Trial
36. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM)
37. A prospective placebocontrolled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): long-term mortality and morbidity
38. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction
39. Hemorrhage vs rethrombosis after thrombolysis for acute myocardial infarction
40. Effect of intravenous APSAC on mortality after acute myocardial infarction
41. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction
42. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications
43. Recent advances in the understanding of contact activation reactions
44. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity
45. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis
46. The prothrombinasecatalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction
47. The bindings of thrombin by fibrin
48. Thrombin activity of fibrin thrombi and soluble plasmic derivatives
49. Plasmin-induced platelet aggregation and platelet release reaction
50. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction
51. Fibrinolysis with acylenzymes: anew approach to thrombolytic therapy
52. Evidence for the progressive up-take of anisoylated plasminogen streptokinase activator complex by clots in human plasma in vitro
53. On the fibrinolytic and thrombolytic properties of active-side p-anisoylated streptokinase plasminogen complex (BRL26921)
54. Acyl-enzymes: a novel class of thrombolytic agents
55. Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction
56. Biological effects of the administration of an equimolar streptokinase-plasminogen complex in man
57. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent
58. Effects of intravenous APSAC on mortality after acute myocardial infarction preliminary report of a placebo-controlled clinical trial
59. Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties
60. Molecular mechanism of action of newer thrombolytic agents
61. In vivo synergism of thrombolytic agents
62. Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergistic thrombolytic agents
63. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for myocardial infarction
64. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli
65. Mutants of human tissue-type plasminogen activator (t-PA): structural aspects and functional properties
66. Receptor-mediated endocytosis of tissue-type plasminogen activator by the human hepatoma cell line Hep G2
67. 2-terminal glutamic acid plasminogen to plasmin
68. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin
69. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
70. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers
71. Autonomous functions of structural domains on human tissue-type plasminogen activator
72. Involvement of finger domain and Kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin
73. A tissue-type plasminogen activator mutant with prolonged clearance in vivo: effect of removal of the growth factor domain
74. Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain
75. Variants of human tissue-type plasminogen activator
76. Expression in E. coli of finger-domain lacking tissue-type plasminogen activator with high fibrin affinity
77. Structure-function analysis with tissue-type plasminogen activator
78. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits
79. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis
80. Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single-chain urokinase type plasminogen activator
81. Artificial exon shuffling between tissue-type plasminogen activator (t-PA) and urokinase (u-PA): a comparative study on the fibrinolytic properties of t-PA/u-PA hybrid proteins
82. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator
83. Construction and expression of hybrid plasminogen activators prepared from tissue-type plasminogen activator and urokinase-type plasminogen activator genes
84. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro
85. Construction and expression of a recombinant antibody-targeted plasminogen activator
86. Antibody-enhanced thrombolysis: targeting of tissue-plasminogen activator in vivo
87. Functional properties of tissueplasminogen activator
88. Biological properties of a kringleless tissue-plasminogen activator (t-PA) mutant
89. Fibrin structural requirements for tissueplasminogen activator mediated plasminogen activation as studied by t-PA deletion mutants
90. Comparison of a novel plasminogen activator (PA) LY210825, and native t-PA in a canine model of coronary artery thrombosis
91. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits
92. Pharmacokinetics and thrombolytic properties of a non-glycosylated mutant of human tissuetype plasminogen activator, lacking the finger growth factor domains, in dogs with copper coil-induced coronary artery thrombosis
93. The role of the endothelium in arterial thrombosis and the influence of antithrombotic therapy
94. Platelets and fibrin in the early development of arterial and venous thrombi
95. The relationship between coronary artery lesions and myocardial infarcts: ulceration of atherosclerotic plaques precipitating coronary thrombosis
96. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation
97. Platelet receptor recognition domain on the γ-chain of human fibrinogen and its synthetic peptide analogues
98. 2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis
99. Hirudin as an inhibitor of thrombin
100. Cloning and expression of a cDNA coding for the anticoagulant hirudo medicinalis
101. Prevention of arterial platelet occlusion by selection thrombin inhibition
102. Recombinant hirudin (r-H) interruption of platelet-dependent thrombus formation
103. Structure and evolution of a 461 as human protein C precursor and its messenger RNA based upon the DNA sequence of cloned human liver cDNAs
104. Preclinical pharmacology of activated protein C
105. The regulation of natural anticoagulant pathways
106. Inhibition of plateletdependent thrombus formation by human activated protein C in a primate model